- FDA requires extended time for review of additional information in New Drug Application (NDA)
- Elagolix clinical trial program largest prospective randomized endometriosis trial conducted to date
- Based on AbbVie's review of the data, the company remains confident in NDA and continues to work with FDA to bring elagolix to patients
- Regulatory submissions for elagolix in uterine fibroids remain on track
PR Newswire
NORTH CHICAGO, Ill., April 10, 2018